ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4032-Chermside-The-Prince-Charles-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
14
trial(s) found.
NCT07190248
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007) (
1084-007
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2560 - Campbelltown - GenesisCare Campbelltown
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07174336
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
PI3Kalpha inhibitor,mutant selective,kinase/helical domain
placebo
Breast cancer
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4032 - Chermside - The Prince Charles Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06960577
Curative
Phase 3
Recruiting
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (
D933RC00002
)
anti-PD-L1 monoclonal antibody
Bladder cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NA
NA
NCT06690775
Advanced
Phase 2
Recruiting
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (
TORL123-002
)
Dexamethasone
Filgrastim
Pegfilgrastim
glucocorticoid
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06682988
Advanced
Phase 2
Recruiting
A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment (
IMGN853-0425
)
anti-FR-alpha antibody-drug conjugate
Fallopian tube cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2305 - New Lambton Heights - Newcastle Private Hospital
VIC
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06561386
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1% (
RELATIVITY1093
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4120 - Greenslopes - Greenslopes Private Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06312137
Curative
Phase 3
Recruiting
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (
TroFuse-019
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06120491
Advanced
Phase 3
Recruiting
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) (
EvoPAR-PR01
)
PARP1-selective inhibitor
placebo
NOT Prostate small cell carcinoma
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5037 - Glandore - Ashford Cancer Centre
NCT06097728
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (
eVOLVE-Meso
)
anti-CTLA4 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
platinum-based antineoplastic agent
Pleural mesothelioma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04938817
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) (
3475-B98
)
anti-PD-1 monoclonal antibody
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
ACTRN12624000582550
Curative
Phase 2
Recruiting
Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (
WOMBAT
) - ANZUP 2201
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12623000552684
Curative
Phase 2
Recruiting
OCEANiC
: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR inhibitor,third generation
EGFR-mutant non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (13)
Approved for marketing (1)
Recruitment Country and State
NSW (14)
QLD (14)
VIC (12)
WA (11)
SA (6)
NZ (3)
Phase
Phase 1 / Phase 2 (1)
Phase 2 (4)
Phase 3 (8)
Trial Type
Advanced (10)
Curative (4)
Cancer Therapy Class
PD-1/PD-L1
50%
PD-1
43%
PD-L1
21%
oestrogen axis
14%
LAG3
14%
AR
14%
androgen axis
14%
CTLA4
14%
KRAS
7%
KRAS G12C
7%
CDK4
7%
CDK6
7%
ER
7%
PI3Kalpha
7%
FR-alpha
7%
ERBB2
7%
TIGIT
7%
Trop2
7%
CYP17A1
7%
PARP
7%
PARP1-selective
7%
ILT4
7%
VEGF
7%
LHRH
7%
EGFR
7%
RET
7%
Facility
4032 - Chermside - The Prince Charles Hospital (14)
3168 - Clayton - Monash Medical Centre (6)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
5042 - Bedford Park - Flinders Medical Centre (2)
6009 - Nedlands - Linear Clinical Research (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3630 - Shepparton - Goulburn Valley Health (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2217 - Kogarah - St George Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
NA
2305 - New Lambton Heights - Newcastle Private Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
5037 - Glandore - Ashford Cancer Centre (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2170 - Liverpool - Liverpool Hospital (1)
3066 - Epping - Northern Hospital (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Urogenital cancer
Breast cancer
Fallopian tube cancer
Gastrointestinal cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Male genital cancers
Prostate cancer
Bladder cancer
Epithelial Ovarian Cancer
Gynaecological cancer
Ovarian cancer
Biliary tract cancer
Hepatobiliary cancer
Mesothelioma
Pleural mesothelioma
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
EGFR-mutant non-small cell lung cancer
Colon adenocarcinoma
Colorectal adenocarcinoma
Colorectal cancer
Differentiated thyroid carcinoma
Endocrine gland cancer
Lower gastrointestinal cancer
Medullary thyroid cancer
Pancreatic cancer
Papillary thyroid cancer
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy